DNMT1 and astrocytoma (excluding glioblastoma): The results revealed that the DNMT1-mediated hypermethylation of the miR-338-5p promoter region could participate in the loss of miR-338-5p expression and the high expression of ETS1 associated with disease severity in astrocytoma patients.